Michael Nebozhyn

发表

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

J. Lunceford, Chunsheng Zhang, T. Mcclanahan, 2018, Science.

Variational self-consistent estimates for viscoplastic polycrystals with highly anisotropic grains

Michael Nebozhyn, P. P. Castañeda, P. Gilormini, 2000 .

Diurnal variation of the human adipose transcriptome and the link to metabolic disease

Xia Yang, Hongyue Dai, Yudong D. He, 2009, BMC Medical Genomics.

EMT is the dominant program in human colon cancer

David B Jackson, David B. Jackson, T. Yeatman, 2011, BMC Medical Genomics.

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Jason G. Jin, M. Ayers, I. Sohn, 2015, Nature Medicine.

New Self-consistent Estimates for the Effective Behavior of Some Model Nonlinear Polycrystals

Michael Nebozhyn, P. P. Castañeda, 1999 .

Variational estimates of the self-consistent type for the effective behaviour of some model nonlinear polycrystals

Michael Nebozhyn, P. P. Castañeda, Pedro Ponte Castañeda, 1997, Proceedings of the Royal Society of London. Series A: Mathematical, Physical and Engineering Sciences.

Microarray data on gene modulation by HIV‐1 in immune cells: 2000–2006

L. Montaner, Michael Nebozhyn, L. Showe, 2006, Journal of leukocyte biology.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

C. Paweletz, H. Dai, I. Feldman, 2010, BMC Medical Genomics.

99% circulating tumor cells with 90% accuracy Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to

M. Yousef, Michael Nebozhyn, A. Loboda, 2013 .

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

M. Ayers, J. Tabernero, Tae Won Kim, 2015, Journal of the National Cancer Institute.

Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.

J. Lunceford, T. Mcclanahan, M. Ayers, 2015 .

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors

J. Lunceford, T. Mcclanahan, M. Ayers, 2015, Journal of Immunotherapy for Cancer.

A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome

Charlotte Soneson, Timothy J. Yeatman, Michael J. Schell, 2015, Clinical Cancer Research.

Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients.

J. Lunceford, T. Mcclanahan, M. Ayers, 2015 .

Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).

J. Lunceford, T. Mcclanahan, M. Ayers, 2015 .

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types

Michael P. Morrissey, J. Lunceford, Chunsheng Zhang, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types.

J. Lunceford, T. Mcclanahan, M. Ayers, 2016 .